How to buy Harrow Health stock | $5.63

Harrow Health, Inc is a drug manufacturers-specialty & generic business based in the US. Harrow Health shares (HROW) are listed on the NASDAQ and all prices are listed in US Dollars. Harrow Health employs 133 staff and has a trailing 12-month revenue of around USD$46.9 million.

How to buy shares in Harrow Health

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Harrow Health. Find the stock by name or ticker symbol: HROW. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Harrow Health reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$5.63, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Harrow Health, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Harrow Health. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Harrow Health share price

Use our graph to track the performance of HROW stocks over time.

Harrow Health shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$5.63
52-week range	USD$3.33 - USD$7.92
50-day moving average	USD$5.8358
200-day moving average	USD$5.8016
Wall St. target price	USD$12.5
PE ratio	9.6418
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.581

Buy Harrow Health shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Harrow Health stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Harrow Health, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Harrow Health price performance over time

Historical closes compared with the close of $5.63 from 2020-12-11

1 week (2021-01-08)	-27.17%
1 month (2020-12-16)	-0.53%
3 months (2020-10-15)	-3.92%
6 months (2020-07-15)	3.68%

1 year (2020-01-15)	-22.13%
2 years (2019-01-15)	-4.58%
3 years (2018-01-12)	204.32%
5 years (2016-01-15)	4.65%

Is Harrow Health under- or over-valued?

Valuing Harrow Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harrow Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Harrow Health's P/E ratio

Harrow Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Harrow Health shares trade at around 10x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Harrow Health's EBITDA

Harrow Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.2 million.

The EBITDA is a measure of a Harrow Health's overall financial performance and is widely used to measure a its profitability.

Harrow Health financials

Revenue TTM	USD$46.9 million
Gross profit TTM	USD$34.4 million
Return on assets TTM	-1%
Return on equity TTM	-8.09%
Profit margin	-3.94%
Book value	$0.985
Market capitalisation	USD$148.8 million

TTM: trailing 12 months

Shorting Harrow Health shares

There are currently 921,362 Harrow Health shares held short by investors – that's known as Harrow Health's "short interest". This figure is 10.2% up from 836,184 last month.

There are a few different ways that this level of interest in shorting Harrow Health shares can be evaluated.

Harrow Health's "short interest ratio" (SIR)

Harrow Health's "short interest ratio" (SIR) is the quantity of Harrow Health shares currently shorted divided by the average quantity of Harrow Health shares traded daily (recently around 130689.64539007). Harrow Health's SIR currently stands at 7.05. In other words for every 100,000 Harrow Health shares traded daily on the market, roughly 7050 shares are currently held short.

However Harrow Health's short interest can also be evaluated against the total number of Harrow Health shares, or, against the total number of tradable Harrow Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Harrow Health's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Harrow Health shares in existence, roughly 40 shares are currently held short) or 0.0384% of the tradable shares (for every 100,000 tradable Harrow Health shares, roughly 38 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Harrow Health.

Find out more about how you can short Harrow Health stock.

Harrow Health share dividends

We're not expecting Harrow Health to pay a dividend over the next 12 months.

Have Harrow Health's shares ever split?

Harrow Health's shares were split on a 1:5 basis on 8 February 2013. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Harrow Health shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Harrow Health shares which in turn could have impacted Harrow Health's share price.

Harrow Health share price volatility

Over the last 12 months, Harrow Health's shares have ranged in value from as little as $3.33 up to $7.92. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harrow Health's is 1.0383. This would suggest that Harrow Health's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Harrow Health overview

Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye drop drug candidates, including SURF-100 and SURF-200; SURF-300, an oral capsule for treating patients suffering from ocular surface diseases, and DED signs and symptoms; Klarity drops to protect and rehabilitate the ocular surface pathology for patients with DED; MELT-100, a drug that is administered sublingually for conscious sedation during cataract surgery; MAY-66 that is used for the treatment of symptoms associated with Peyronie's disease; MAY-44, a non-estrogen topical analgesic gel; and other drug candidates for rare diseases. In addition, the company engages in the development of MAY-88, an oral anhydrous extend release suspension of pentosan polysulfate sodium for interstitial cystitis. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.

Frequently asked questions

• What percentage of Harrow Health is owned by insiders or institutions?

  Currently 7.513% of Harrow Health shares are held by insiders and 46.636% by institutions.

• How many people work for Harrow Health?

  Latest data suggests 133 work at Harrow Health.

• When does the fiscal year end for Harrow Health?

  Harrow Health's fiscal year ends in December.

• Where is Harrow Health based?

  Harrow Health's address is: 12264 El Camino Real, San Diego, CA, United States, 92130

• What is Harrow Health's ISIN number?

  Harrow Health's international securities identification number is: US4158581094

• What is Harrow Health's CUSIP number?

  Harrow Health's Committee on Uniform Securities Identification Procedures number is: 415858109